Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025
Evaxion (NASDAQ: EVAX), a clinical-stage TechBio company focused on AI-powered vaccine development, has scheduled its Q1 2025 financial results announcement and business update for May 27, 2025, before Nasdaq CM market opening. The company's management will host a conference call and webcast at 14:30 CET/08:30 EST on the same day. Investors and the public can participate in the event by registering in advance to receive dial-in details and a PIN code. The presentation will be followed by a Q&A session, and a recording will be made available on Evaxion's website after the event.
Evaxion (NASDAQ: EVAX), un'azienda TechBio in fase clinica specializzata nello sviluppo di vaccini potenziati dall'IA, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 e l'aggiornamento aziendale per il 27 maggio 2025, prima dell'apertura del mercato Nasdaq CM. La direzione dell'azienda terrà una conference call e una webcast alle 14:30 CET/08:30 EST dello stesso giorno. Investitori e pubblico possono partecipare all'evento registrandosi in anticipo per ricevere i dettagli per la chiamata e un codice PIN. La presentazione sarà seguita da una sessione di domande e risposte e una registrazione sarà disponibile sul sito web di Evaxion dopo l'evento.
Evaxion (NASDAQ: EVAX), una empresa TechBio en fase clínica centrada en el desarrollo de vacunas impulsadas por IA, ha programado el anuncio de resultados financieros del primer trimestre de 2025 y actualización comercial para el 27 de mayo de 2025, antes de la apertura del mercado Nasdaq CM. La dirección de la empresa realizará una llamada en conferencia y una transmisión en vivo a las 14:30 CET/08:30 EST del mismo día. Los inversores y el público pueden participar en el evento registrándose previamente para recibir los detalles de acceso y un código PIN. La presentación será seguida por una sesión de preguntas y respuestas, y la grabación estará disponible en el sitio web de Evaxion después del evento.
Evaxion (NASDAQ: EVAX)은 AI 기반 백신 개발에 중점을 둔 임상 단계의 테크바이오 기업으로, 2025년 1분기 재무 결과 발표 및 사업 업데이트를 2025년 5월 27일 나스닥 CM 시장 개장 전으로 예정했습니다. 회사 경영진은 같은 날 14:30 CET/08:30 EST에 컨퍼런스 콜과 웹캐스트를 진행할 예정입니다. 투자자와 일반인은 사전에 등록하여 전화 접속 정보와 PIN 코드를 받아 행사에 참여할 수 있습니다. 발표 후 질의응답 시간이 있으며, 행사 후 녹화본이 Evaxion 웹사이트에 게시될 예정입니다.
Evaxion (NASDAQ : EVAX), une entreprise TechBio en phase clinique spécialisée dans le développement de vaccins assisté par IA, a programmé l'annonce des résultats financiers du premier trimestre 2025 et une mise à jour commerciale pour le 27 mai 2025, avant l'ouverture du marché Nasdaq CM. La direction de l'entreprise animera une conférence téléphonique et une webdiffusion à 14h30 CET/08h30 EST le même jour. Les investisseurs et le public peuvent participer à l'événement en s'inscrivant à l'avance pour recevoir les informations d'appel et un code PIN. La présentation sera suivie d'une session de questions-réponses, et un enregistrement sera disponible sur le site web d'Evaxion après l'événement.
Evaxion (NASDAQ: EVAX), ein klinisch tätiges TechBio-Unternehmen mit Fokus auf KI-gestützte Impfstoffentwicklung, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 und ein Geschäftsupdate für den 27. Mai 2025 vor Öffnung des Nasdaq CM-Marktes geplant. Das Management des Unternehmens wird am selben Tag um 14:30 CET/08:30 EST eine Telefonkonferenz und einen Webcast abhalten. Investoren und die Öffentlichkeit können an der Veranstaltung teilnehmen, indem sie sich im Voraus registrieren, um Einwahldaten und einen PIN-Code zu erhalten. Der Präsentation folgt eine Fragerunde, und eine Aufzeichnung wird nach der Veranstaltung auf der Website von Evaxion verfügbar sein.
- None.
- None.
COPENHAGEN, Denmark, May 23, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its first quarter 2025 financial results on Tuesday, May 27, 2025, before opening of the Nasdaq CM.
Evaxion’s Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions. This event is free, open to the public and encouraged.
To join the conference call, listen to the presentation and ask verbal questions, please register in advance via this link to receive the dial-in telephone numbers and a unique PIN code. The call can be accessed 15 minutes prior to the start of the live event.
To join the webcast, please click on this link. The webcast recording will be available on our website shortly after the event.
Contact information
Evaxion A/S
Mads Kronborg
Vice President, Investor Relations & Communication
+45 53 54 82 96
mak@evaxion.ai
About EVAXION
Evaxion A/S is a pioneering TechBio company based upon its AI platform, AI-Immunology™. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Based upon AI-Immunology™, Evaxion has developed a clinical-stage oncology pipeline of novel personalized vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. Evaxion is committed to transforming patients’ lives by providing innovative and targeted treatment options. For more information about Evaxion and its groundbreaking AI-Immunology™ platform and vaccine pipeline, please visit our website.
Forward-looking statement
This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at www.sec.gov. We do not assume any obligation to update any forward-looking statements except as required by law.
FAQ
When will Evaxion (EVAX) release its Q1 2025 earnings?
What time is Evaxion's Q1 2025 earnings call?
How can I join Evaxion's Q1 2025 earnings conference call?
Will there be a webcast of Evaxion's Q1 2025 earnings call?
